Expressions of endocan in patients with meningiomas and gliomas

dc.contributor.authorAtukeren, Pınar
dc.contributor.authorKunbaz, Ahmad
dc.contributor.authorTürk, Okan
dc.contributor.authorKemerdere, Rahsan
dc.contributor.authorUlu, Mustafa Onur
dc.contributor.authorTanrıverdi, Taner
dc.contributor.buuauthorİnanır, Nursel Türkmen
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Adli Tıp Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-4047-6455tr_TR
dc.contributor.scopusid57188706721tr_TR
dc.date.accessioned2022-12-13T12:52:28Z
dc.date.available2022-12-13T12:52:28Z
dc.date.issued2016-06-30
dc.description.abstractObjective. Endocan has been shown to be a marker for several cancers and may show degree of malignancy. The aim of this study is to assess tissue levels of endocan in common brain tumors, namely, meningiomas, low-grade gliomas (LGGs), and high-grade gliomas (HGGs). Patients and Methods. Endocan was assayed by commercially available enzyme linked immunosorbent assay (ELISA) kits in a total of 50 brain tumors (20 meningiomas, 19 LGGs, and 20 HGGs) and 15 controls. The results were compared to control brain tissues. Results. Each tumor group showed significant higher levels of endocan compared to controls (p < 0.05). In addition, endocan levels showed steady increase from the least (meningiomas) to the most (HGGs) malignant tumors and positive correlation was noted between the degree of malignancy and endocan level (p = 0.0001). Conclusion. Endocan, a vital molecule for angiogenesis, is expressed in common brain tumors and results suggest that endocan could be a marker for malignancy.en_US
dc.description.sponsorshipİstanbul Üniversitesi - 55673tr_TR
dc.identifier.citationAtukeren, P. vd. (2016). "Expressions of endocan in patients with meningiomas and gliomas". ed. Lance A. L. Disease Markers, 2016.en_US
dc.identifier.issn0278-0240
dc.identifier.issn1875-8630
dc.identifier.pubmed27528791tr_TR
dc.identifier.scopus2-s2.0-84982153572tr_TR
dc.identifier.urihttps://doi.org/10.1155/2016/7157039
dc.identifier.urihttps://www.hindawi.com/journals/dm/2016/7157039/
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978841/
dc.identifier.urihttp://hdl.handle.net/11452/29860
dc.identifier.volume2016tr_TR
dc.identifier.wos000381130500001tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherHindawien_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalDisease Markersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiotechnology & applied microbiologyen_US
dc.subjectGenetics & heredityen_US
dc.subjectResearch & experimental medicineen_US
dc.subjectPathologyen_US
dc.subjectCell-specific molecule-1en_US
dc.subjectMarkeren_US
dc.subjectEsm-1en_US
dc.subjectSurvivalen_US
dc.subjectInvasionen_US
dc.subjectCanceren_US
dc.subject.emtreeAnticonvulsive agenten_US
dc.subject.emtreeEndocanen_US
dc.subject.emtreeProteinen_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.emtreeESM1 protein, humanen_US
dc.subject.emtreeProteoglycanen_US
dc.subject.emtreeTumor markeren_US
dc.subject.emtreeTumor proteinen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeCancer radiotherapyen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeComparative studyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeEnzyme linked immunosorbent assayen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeGliomaen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeMeningiomaen_US
dc.subject.emtreeNuclear magnetic resonance imagingen_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreeProtein determinationen_US
dc.subject.emtreeProtein expressionen_US
dc.subject.emtreeSeizureen_US
dc.subject.emtreeSurvival timeen_US
dc.subject.emtreeBrain tumoren_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeCase control studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGliomaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMeningiomaen_US
dc.subject.emtreeMetabolismen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreePrognosisen_US
dc.subject.meshAdulten_US
dc.subject.meshBiomarkers, tumoren_US
dc.subject.meshCase-control studiesen_US
dc.subject.meshBrain neoplasmsen_US
dc.subject.meshEnzyme-linked immunosorbent assayen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshGliomaen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMeningeal neoplasmsen_US
dc.subject.meshMeningiomaen_US
dc.subject.meshNeoplasm proteinsen_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshPrognosisen_US
dc.subject.meshProteoglycansen_US
dc.subject.scopusDermatan Sulfate Proteoglycan; Human ESM1 Protein; Proteoglycanen_US
dc.subject.wosBiotechnology & applied microbiologyen_US
dc.subject.wosGenetics & heredityen_US
dc.subject.wosMedicine, research & experimentalen_US
dc.subject.wosPathologyen_US
dc.titleExpressions of endocan in patients with meningiomas and gliomasen_US
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Türkmen_vd_2016.pdf
Size:
548.15 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: